StockNews.AI
RPID
StockNews.AI
7 days

Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

1. RPID reported $7.3 million revenue, up 10% year-over-year. 2. Recurring revenue grew by 15%, indicating strong customer retention. 3. Gross margin improved to 4%, reflecting better cost management. 4. The company secured a $45 million loan to enhance financial stability. 5. RPID reaffirms revenue guidance of at least $32 million for 2025.

14m saved
Insight
Article

FAQ

Why Bullish?

The strong revenue growth coupled with improving margins and financial stability positions RPID favorably. Historically, similar financial performances have led to positive market reactions.

How important is it?

The article details significant revenue and operational improvements, which are critical for investor confidence. Positive earnings reports often yield strong investor interest and influence stock price.

Why Short Term?

Immediate market reactions will be influenced by the recent financial results and guidance. Positive investor sentiment can drive short-term stock appreciation.

Related Companies

TRXCAXNXMXL
Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect broad-based, consistent execution across the business,” said Robert Spignesi, President and CEO. “Total revenue increased 10%, driven by an 18% increase in Service revenue. Product revenue increased by 6%, led by mid-teens growth in consumables. With continued strong customer interest in Growth Direct and meaningful progress across our broader business, we are reiterating our full-year 2025 revenue guidance.” “In addition, this morning we announced a new five-year, $45 million term loan facility, with $20 million funded upfront with highly favorable terms, including no financial or liquidity covenants,” continued Spignesi. “This facility significantly strengthens our financial position and reinforces our ability to achieve positive cash flow. Our strategic priorities remain unchanged, and this capital supports our continued focus on delivering significant long-term revenue growth, gross margin expansion and shareholder value.” Second Quarter Financial Results Total revenue for the second quarter of 2025 increased 10% to $7.3 million compared to $6.6 million in the second quarter of 2024. The Company placed four new Growth Direct® systems and completed the validation of two customer systems compared to five placements and five validations in the second quarter of 2024. Product revenue increased by 6% to $4.8 million, compared to $4.5 million in the second quarter of 2024. Service revenue increased by 18% to $2.5 million, compared to $2.1 million in the second quarter of 2024. Recurring revenue increased by 15% to $4.4 million, compared to $3.8 million in the second quarter of 2024. Total cost of revenue was $7.0 million in the second quarter of 2025, an increase of 3% compared to $6.8 million in the second quarter of 2024. Gross margin was positive 4%, or positive $0.3 million, compared to negative 3%, or negative $0.2 million in the second quarter of 2024. Total operating expenses decreased by 6% to $12.4 million in the second quarter of 2025, compared to $13.2 million in the second quarter of 2024. General and administrative expenses increased 4%, research and development expenses decreased by 14%, and sales and marketing expenses decreased by 14%, in each case compared to the second quarter of 2024. Net loss for the second quarter of 2025 was $11.9 million, compared to $12.6 million in the second quarter of 2024. Net loss per share for the second quarter of 2025 was $0.27, compared to $0.29 in the second quarter of 2024. Cash, cash equivalents, short-term investments, and restricted cash were approximately $32 million as of June 30, 2025. 2025 Outlook The Company is reaffirming its full year 2025 total revenue guidance of at least $32.0 million. Loan Facility In a separate release issued today, the Company announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. The Company received $20 million at close through the first tranche and has access to two additional tranches totaling $20 million, subject to the achievement of certain commercial and operational milestones. A fourth tranche of $5 million is available at the lender's discretion. For additional details regarding this facility, please refer to the related press release at https://investors.rapidmicrobio.com/news-and-events/news-releases. Webcast Details The Company will host a conference call before the market opens today, August 12, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn. Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts. Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; the Company's goal of achieving cash flow breakeven; the Company's newly-announced debt facility; the Company’s ability to reduce product costs, and improve manufacturing efficiency and service productivity; and the Company's ability to advance its priorities of accelerating Growth Direct system placements, improving gross margins and innovating new products. In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder, the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law. RAPID MICRO BIOSYSTEMS, INC.Unaudited Condensed Consolidated Statements of Operations(in thousands, except share and per share amounts)  Three Months Ended June 30, Six Months Ended June 30,  2025 2024 2025 2024 Revenue:                Product revenue$4,802  $4,537  $8,903  $8,250  Service revenue 2,460   2,081   5,564   3,979  Total revenue 7,262   6,618   14,467   12,229  Costs and operating expenses:                Cost of product revenue 5,315   4,917   10,344   10,090  Cost of service revenue 1,672   1,890   3,444   3,851  Research and development 3,230   3,744   6,854   7,586  Sales and marketing 3,114   3,627   5,865   6,908  General and administrative 6,079   5,818   11,769   11,445  Total costs and operating expenses 19,410   19,996   38,276   39,880  Loss from operations (12,148)  (13,378)  (23,809)  (27,651) Other income (expense):                Interest income, net 351   838   817   1,821  Other expense, net (50)  (23)  (111)  (52) Total other income, net 301   815   706   1,769  Loss before income taxes (11,847)  (12,563)  (23,103)  (25,882) Income tax expense 11   15   18   18  Net loss$(11,858) $(12,578)  (23,121)  (25,900) Net loss per share — basic and diluted$(0.27) $(0.29) $(0.52) $(0.60) Weighted average common shares outstanding —basic and diluted 44,648,602   43,616,501   44,321,566   43,431,170    RAPID MICRO BIOSYSTEMS, INC.Unaudited Condensed Consolidated Balance Sheets(in thousands)  June 30,2025 December 31,2024 Assets      Current assets:      Cash and cash equivalents$18,333 $16,911 Short-term investments 12,922  33,821 Accounts receivable 6,048  7,519 Inventory 20,560  20,200 Prepaid expenses and other current assets 2,283  2,466 Total current assets 60,146  80,917 Property and equipment, net 10,205  11,193 Right-of-use assets, net 4,640  5,163 Other long-term assets 311  531 Restricted cash 284  365 Total assets$75,586 $98,169 Liabilities and Stockholders’ Equity      Current liabilities:      Accounts payable$3,334 $2,535 Accrued expenses and other current liabilities 5,678  7,217 Deferred revenue 6,136  6,599 Lease liabilities, short-term 1,255  1,214 Total current liabilities 16,403  17,565 Lease liabilities, long-term 4,324  4,954 Other long-term liabilities 314  298 Total liabilities 21,041  22,817 Total stockholders’ equity 54,545  75,352 Total liabilities and stockholders’ equity$75,586 $98,169   RAPID MICRO BIOSYSTEMS, INC.Unaudited Cash, Cash Equivalents and Investments(in thousands)  June 30,2025 December 31,2024 Cash and cash equivalents$18,333 $16,911 Short-term investments 12,922  33,821 Cash, cash equivalents and investments$31,255 $50,732 

Related News